Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -397.38% is 105% below its 5-year average of -193.95%, around the middle of its 5-year range (-969.28%–-65.99%).
As of the fiscal period ended Tuesday, June 30, 2026. 36.51% above its 12-month average of -625.94%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -397.38%.
RETURN ON EQUITY (ROE)
-397.38%
RETURN ON EQUITY (ROE) AVG TTM
-625.94%
RETURN ON EQUITY (ROE) AVG 3Y
-426.60%
RETURN ON EQUITY (ROE) AVG 5Y
-193.95%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+36.51%
CURRENT VS 3Y AVG
+6.85%
CURRENT VS 5Y AVG
-104.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-845.91%
vs the sector median at left
NervGen Pharma Corp. Common stock
Market Cap
$145.89M
Return on Equity (ROE)
-397.38%
TTM Avg
-625.94%
3Y Avg
-426.60%
5Y Avg
-193.95%
Market Cap
$145.96M
Return on Equity (ROE)
-21.38%
TTM Avg
-42.33%
3Y Avg
-37.95%
5Y Avg
-45.57%
Market Cap
$146.01M
Return on Equity (ROE)
-131.85%
TTM Avg
-36.69%
3Y Avg
-135.43%
5Y Avg
-129.92%
Market Cap
$145.33M
Return on Equity (ROE)
-43.40%
TTM Avg
-27.96%
3Y Avg
-44.92%
5Y Avg
-37.65%
Market Cap
$146.83M
Return on Equity (ROE)
-93.22%
TTM Avg
-92.28%
3Y Avg
-73.94%
5Y Avg
-53.80%
Market Cap
$147.13M
Return on Equity (ROE)
-69.78%
TTM Avg
-41.37%
3Y Avg
-26.34%
5Y Avg
-26.08%
Market Cap
$147.34M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$147.35M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$144.06M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $145.89M | -397.38% | -625.94% | -426.60% | -193.95% |
| Anavex Life Sciences Corp. (AVXL)vs › | $145.96M | -21.38% | -42.33% | -37.95% | -45.57% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.01M | -131.85% | -36.69% | -135.43% | -129.92% |
| Protara Therapeutics, Inc. (TARA)vs › | $145.33M | -43.40% | -27.96% | -44.92% | -37.65% |
| Codexis, Inc. (CDXS)vs › | $146.83M | -93.22% | -92.28% | -73.94% | -53.80% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.13M | -69.78% | -41.37% | -26.34% | -26.08% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $147.34M | -183.44% | -114.28% | -67.72% | -46.03% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $147.35M | -59.40% | -255.06% | -160.44% | -112.56% |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | 68.12% | -94.32% | -166.28% | -128.51% |
| Nyxoah S.A. (NYXH)vs › | $142.60M | -120.33% | -117.87% | -76.44% | -55.77% |
ROE
-397.4%
ROA
-76.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -397.38% |
| 2026-03-31 | -854.50% |
| 2024-12-31 | -969.28% |
| 2024-09-30 | -263.74% |
| 2024-06-30 | -187.45% |
| 2024-03-31 | -107.41% |
| 2023-09-30 | -388.87% |
| 2023-06-30 | -244.21% |
| 2023-03-31 | -208.52% |
| 2022-12-31 | -159.66% |
| 2022-09-30 | -106.02% |
| 2022-06-30 | -178.98% |
| 2022-03-31 | -108.06% |
| 2021-12-31 | -65.99% |
| 2021-09-30 | -150.66% |
| 2021-06-30 | -148.39% |
| 2021-03-31 | -217.29% |
| 2020-12-31 | -180.93% |
| 2020-09-30 | -95.85% |
| 2020-06-30 | -177.83% |
| 2020-03-31 | -196.78% |
| 2019-12-31 | -162.04% |
| 2019-09-30 | -117.53% |
| 2019-06-30 | -66.59% |
| 2019-03-31 | -47.09% |
| 2018-12-31 | -54.50% |
| 2018-09-30 | -17.52% |
